Immatics N.V. (IMTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMTX POWR Grades
- IMTX scores best on the Growth dimension, with a Growth rank ahead of 66.99% of US stocks.
- The strongest trend for IMTX is in Momentum, which has been heading down over the past 51 weeks.
- IMTX ranks lowest in Momentum; there it ranks in the 4th percentile.
IMTX Stock Summary
- Immatics NV's stock had its IPO on October 5, 2018, making it an older stock than only 8.12% of US equities in our set.
- IMTX's price/sales ratio is 25.32; that's higher than the P/S ratio of 91.79% of US stocks.
- Over the past twelve months, IMTX has reported earnings growth of 321.71%, putting it ahead of 92.39% of US stocks in our set.
- Stocks that are quantitatively similar to IMTX, based on their financial statements, market capitalization, and price volatility, are ALLO, ARWR, IONS, ARVN, and RETA.
- Visit IMTX's SEC page to see the company's official filings. To visit the company's web site, go to www.immatics.com.
IMTX Stock Price Chart Interactive Chart >
IMTX Price/Volume Stats
|Current price||$13.85||52-week high||$18.42|
|Prev. close||$14.16||52-week low||$9.58|
|Day high||$14.35||Avg. volume||337,704|
|50-day MA||$13.21||Dividend yield||N/A|
|200-day MA||$12.02||Market Cap||871.29M|
Immatics N.V. (IMTX) Company Bio
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.
Most Popular Stories View All
IMTX Latest News Stream
|Loading, please wait...|
IMTX Latest Social Stream
View Full IMTX Social Stream
Latest IMTX News From Around the Web
Below are the latest news stories about Immatics NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
On average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402Cash and cash equivalents as well as Other financial assets of $229.1 million1 (€192.8 million) as of June 30, 2021, funding company operations into 2023 Tuebingen, Ger
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things.
Tuebingen, Germany and Houston, Texas, May 26, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced changes to its Board of Directors. Christof Hettich, L.L.D., Managing Partner and founding member of the dievini Hopp BioTech holding GmbH & Co. KG, has decided to step down from Immatics’ Board of Directors. He has been a member of Immatics’ Board of Directors since 2006. Former Immatics Board member Friedrich von Bohlen und Halbach, PhD, Managing Partner and co-founder of dievini Hopp BioTech Holding GmbH & Co. KG has been nominated to be his successor. The election will take place at Immatics’ Annual General Meeting on June 17, 2021. Peter Chambré...
Immatics N.V. (NASDAQ:IMTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immatics N.V. ( NASDAQ:IMTX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...
IMTX Price Returns